These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24819296)

  • 21. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
    Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
    Front Immunol; 2018; 9():1955. PubMed ID: 30214445
    [No Abstract]   [Full Text] [Related]  

  • 22. Interaction of human PD-L1 and B7-1.
    Butte MJ; Peña-Cruz V; Kim MJ; Freeman GJ; Sharpe AH
    Mol Immunol; 2008 Aug; 45(13):3567-72. PubMed ID: 18585785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
    Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
    Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
    Durgan K; Ali M; Warner P; Latchman YE
    Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
    Chen G; Huang AC; Zhang W; Zhang G; Wu M; Xu W; Yu Z; Yang J; Wang B; Sun H; Xia H; Man Q; Zhong W; Antelo LF; Wu B; Xiong X; Liu X; Guan L; Li T; Liu S; Yang R; Lu Y; Dong L; McGettigan S; Somasundaram R; Radhakrishnan R; Mills G; Lu Y; Kim J; Chen YH; Dong H; Zhao Y; Karakousis GC; Mitchell TC; Schuchter LM; Herlyn M; Wherry EJ; Xu X; Guo W
    Nature; 2018 Aug; 560(7718):382-386. PubMed ID: 30089911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo.
    Habicht A; Kewalaramani R; Vu MD; Demirci G; Blazar BR; Sayegh MH; Li XC
    Am J Transplant; 2007 Dec; 7(12):2683-92. PubMed ID: 17924994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Importance of CD80/CD86-CD28 interactions in the recognition of target cells by CD8+CD122+ regulatory T cells.
    Shi Z; Rifa'i M; Lee YH; Shiku H; Isobe K; Suzuki H
    Immunology; 2008 May; 124(1):121-8. PubMed ID: 18205792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
    Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
    J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
    Hombach A; Wieczarkowiecz A; Marquardt T; Heuser C; Usai L; Pohl C; Seliger B; Abken H
    J Immunol; 2001 Dec; 167(11):6123-31. PubMed ID: 11714771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80.
    Haile ST; Bosch JJ; Agu NI; Zeender AM; Somasundaram P; Srivastava MK; Britting S; Wolf JB; Ksander BR; Ostrand-Rosenberg S
    J Immunol; 2011 Jun; 186(12):6822-9. PubMed ID: 21555531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
    Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
    J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
    Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM
    Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
    Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
    Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation.
    Chai JG; Vendetti S; Amofah E; Dyson J; Lechler R
    J Immunol; 2000 Sep; 165(6):3037-42. PubMed ID: 10975813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.
    Park JJ; Omiya R; Matsumura Y; Sakoda Y; Kuramasu A; Augustine MM; Yao S; Tsushima F; Narazaki H; Anand S; Liu Y; Strome SE; Chen L; Tamada K
    Blood; 2010 Aug; 116(8):1291-8. PubMed ID: 20472828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
    Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of experimental blood stage malaria through blockade of the B7/CD28 T-cell costimulatory pathway.
    Taylor-Robinson AW; Smith EC
    Immunology; 1999 Mar; 96(3):498-504. PubMed ID: 10233733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of costimulation and the microenvironment on antigen presentation by leukemic cells.
    Buggins AG; Lea N; Gäken J; Darling D; Farzaneh F; Mufti GJ; Hirst WJ
    Blood; 1999 Nov; 94(10):3479-90. PubMed ID: 10552958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab.
    Cavalcante L; Chandana S; Lakhani N; Enstrom A; LeBlanc H; Schmalz J; Lengyel K; Schneider F; Thomas H; Chisamore MJ; Peng SL; Naumovski A; Davar D
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39142718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.